AGORACOM News Flash

AGORACOM WIRE .... WEEKEND EDITION

TOP STORY .... AGORACOM Launches GraphiteStocksBlog.com

We're proud to announce the launch of GraphiteStocksBlog.com a website dedicated to the needs of investors and companies in the fast growing Graphite industry.

INAUGURAL GRAPHITE SPONSORS

AGORACOM INTERVIEWS ERIC SPROTT: Eric Discusses UC Resources $1.5M Investment INTO Sprott + Current And Future Silver Path

Message: HAE & Angiotech Enter License, Distribution and Supply Agreements ........

Reply New Message

« Prev Message Back To Forum Go to Threaded View Next Message »

Cooky

Rank: [?]

President

Points: [?]

14216

Rating: [?]

Votes: 74 Score: 3.5

Currently 3.5/5 Stars.

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.

This message has been removed due to a violation of Agoracom's Six Rules of Use

HAE & Angiotech Enter License, Distribution and Supply Agreements ........

posted on Jul 03, 09 11:19PM

Haemacure and Angiotech Enter License, Distribution and Supply Agreements for Haemacure's All-Human Fibrin Sealant and Thrombin Products

Press Release
Source: HAEMACURE CORPORATION
On Wednesday June 3, 2009, 10:47 am EDT

About Angiotech

Angiotech Pharmaceuticals, Inc. is a global specialty pharmaceutical and medical device company with over 1,500 dedicated employees. Angiotech discovers, develops and markets innovative treatment solutions for diseases or complications associated with medical device implants, surgical interventions and acute injury. To find out more about Angiotech (NASDAQ:ANPI, TSX: ANP), please visit its website at www.angiotech.com.

Forward-looking Statements

Certain of the statements contained in this news release are forward-looking statements. Such statements, based as they are on the current expectations of management, inherently involve numerous risks and uncertainties, known and unknown. Some examples of known risks are: the impact of general economic conditions, general conditions in the biotech industry, changes in the regulatory environment in the jurisdictions in which Haemacure does business, stock market volatility, fluctuations in costs, and changes to the competitive environment due to consolidation or otherwise. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements. Haemacure disclaims any intention or obligation to update these statements.

For further information

Haemacure Corporation: Joseph Galli, Chairman and CEO, (514) 990-7074, jgalli@haemacure.ca
Gilles Lemieux, Secretary, (514) 282-3350 ext. 22, ir@haemacure.ca
www.haemacure.com